Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Despite resilient demand, healthcare has taken a hit along with the rest of the market. Amgen could boost profits ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Amgen (AMGN) stock in focus as Sandoz files antitrust lawsuit alleging that the company blocked copycats from targeting its ...

Shares of UnitedHealth and Amgen are posting losses Thursday morning, propelling the Dow Jones Industrial Average selloff.

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...